These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. BCG, levamisole and transfer factor in the treatment of cancer. Spitler LE Prog Exp Tumor Res; 1980; 25():178-92. PubMed ID: 6986631 [No Abstract] [Full Text] [Related]
5. Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers. Morales A; Pang AS J Urol; 1986 Jan; 135(1):191-3. PubMed ID: 3941461 [TBL] [Abstract][Full Text] [Related]
10. BCG immunotherapy in superficial cancer of the bladder. Levinson IP; van Blerk PJ S Afr J Surg; 1985 Jun; 23(2):53-4. PubMed ID: 3895464 [No Abstract] [Full Text] [Related]
11. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer. Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662 [No Abstract] [Full Text] [Related]
12. [Superficial bladder tumors. Preliminary results of a prospective study comparing endovesical BCG, adriamycin and thio-tepa]. Martínez-Piñeiro JA; de la Peña J; Hidalgo L; Cisneros J; Jiménez León J; Machuca J; Perdices C Arch Esp Urol; 1985; 38(6):545-53. PubMed ID: 3938633 [No Abstract] [Full Text] [Related]
13. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer. Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026 [TBL] [Abstract][Full Text] [Related]
14. Developments in immunotherapy. Krakowka S Mod Vet Pract; 1981 Jun; 62(6):447-51. PubMed ID: 6166843 [TBL] [Abstract][Full Text] [Related]